| Segment and Geographic Area Information |
Segment and Geographic Area Information AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods. Substantially all of AbbVie's net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues: | | | | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2020 | | 2019 | | 2018 | | Immunology | | | | | | | Humira | United States | $ | 16,112 | | | $ | 14,864 | | | $ | 13,685 | | | International | 3,720 | | | 4,305 | | | 6,251 | | | Total | $ | 19,832 | | | $ | 19,169 | | | $ | 19,936 | | | Skyrizi | United States | $ | 1,385 | | | $ | 311 | | | $ | — | | | International | 205 | | | 44 | | | — | | | Total | $ | 1,590 | | | $ | 355 | | | $ | — | | | Rinvoq | United States | $ | 653 | | | $ | 47 | | | $ | — | | | International | 78 | | | — | | | — | | | Total | $ | 731 | | | $ | 47 | | | $ | — | | | Hematologic Oncology | | | | | | | Imbruvica | United States | $ | 4,305 | | | $ | 3,830 | | | $ | 2,968 | | | Collaboration revenues | 1,009 | | | 844 | | | 622 | | | Total | $ | 5,314 | | | $ | 4,674 | | | $ | 3,590 | | | Venclexta | United States | $ | 804 | | | $ | 521 | | | $ | 247 | | | International | 533 | | | 271 | | | 97 | | | Total | $ | 1,337 | | | $ | 792 | | | $ | 344 | | | Aesthetics | | | | | | Botox Cosmetic (a) | United States | $ | 687 | | | $ | — | | | $ | — | | | International | 425 | | | — | | | — | | | Total | $ | 1,112 | | | $ | — | | | $ | — | | Juvederm Collection (a) | United States | $ | 318 | | | $ | — | | | $ | — | | | International | 400 | | | — | | | — | | | Total | $ | 718 | | | $ | — | | | $ | — | | Other Aesthetics (a) | United States | $ | 666 | | | $ | — | | | $ | — | | | International | 94 | | | — | | | — | | | Total | $ | 760 | | | $ | — | | | $ | — | | | Neuroscience | | | | | | Botox Therapeutic (a) | United States | $ | 1,155 | | | $ | — | | | $ | — | | | International | 232 | | | — | | | — | | | Total | $ | 1,387 | | | $ | — | | | $ | — | | Vraylar (a) | United States | $ | 951 | | | $ | — | | | $ | — | | | | | | | | | | | | | | | | | Duodopa | United States | $ | 103 | | | $ | 97 | | | $ | 80 | | | International | 391 | | | 364 | | | 350 | | | Total | $ | 494 | | | $ | 461 | | | $ | 430 | | Ubrelvy (a) | United States | $ | 125 | | | $ | — | | | $ | — | | | | | | | | | | | | | | | | Other Neuroscience (a) | United States | $ | 528 | | | $ | — | | | $ | — | | | International | 11 | | | — | | | — | | | Total | $ | 539 | | | $ | — | | | $ | — | |
| | | | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2020 | | 2019 | | 2018 | | Eye Care | | | | | | Lumigan/Ganfort (a) | United States | $ | 165 | | | $ | — | | | $ | — | | | International | 213 | | | — | | | — | | | Total | $ | 378 | | | $ | — | | | $ | — | | Alphagan/Combigan (a) | United States | $ | 223 | | | $ | — | | | $ | — | | | International | 103 | | | — | | | — | | | Total | $ | 326 | | | $ | — | | | $ | — | | Restasis (a) | United States | $ | 755 | | | $ | — | | | $ | — | | | International | 32 | | | — | | | — | | | Total | $ | 787 | | | $ | — | | | $ | — | | Other Eye Care (a) | United States | $ | 305 | | | $ | — | | | $ | — | | | International | 388 | | | — | | | — | | | Total | $ | 693 | | | $ | — | | | $ | — | | | Women's Health | | | | | | Lo Loestrin (a) | United States | $ | 346 | | | $ | — | | | $ | — | | | International | 10 | | | — | | | — | | | Total | $ | 356 | | | $ | — | | | $ | — | | | Orilissa/Oriahnn | United States | $ | 121 | | | $ | 91 | | | $ | 11 | | | International | 4 | | | 2 | | | — | | | Total | $ | 125 | | | $ | 93 | | | $ | 11 | | Other Women's Health (a) | United States | $ | 181 | | | $ | — | | | $ | — | | | International | 11 | | | — | | | — | | | Total | $ | 192 | | | $ | — | | | $ | — | | | Other Key Products | | | | | | | Mavyret | United States | $ | 785 | | | $ | 1,473 | | | $ | 1,614 | | | International | 1,045 | | | 1,420 | | | 1,824 | | | Total | $ | 1,830 | | | $ | 2,893 | | | $ | 3,438 | | | Creon | United States | $ | 1,114 | | | $ | 1,041 | | | $ | 928 | | | Lupron | United States | $ | 600 | | | $ | 720 | | | $ | 726 | | | International | 152 | | | 167 | | | 166 | | | Total | $ | 752 | | | $ | 887 | | | $ | 892 | | Linzess/Constella (a) | United States | $ | 649 | | | $ | — | | | $ | — | | | International | 18 | | | — | | | — | | | Total | $ | 667 | | | $ | — | | | $ | — | | | Synthroid | United States | $ | 771 | | | $ | 786 | | | $ | 776 | | | All other | | $ | 2,923 | | | $ | 2,068 | | | $ | 2,408 | | | Total net revenues | $ | 45,804 | | | $ | 33,266 | | | $ | 32,753 | |
(a)Net revenues include Allergan product revenues from the date of the acquisition, May 8, 2020, through December 31, 2020. Net revenues to external customers by geographic area, based on product shipment destination, were as follows: | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2020 | | 2019 | | 2018 | | United States | $ | 34,879 | | | $ | 23,907 | | | $ | 21,524 | | | Japan | 1,198 | | | 1,211 | | | 1,591 | | | Canada | 1,159 | | | 813 | | | 730 | | | Germany | 1,049 | | | 909 | | | 1,292 | | | France | 797 | | | 695 | | | 783 | | | Australia | 527 | | | 395 | | | 350 | | | United Kingdom | 509 | | | 372 | | | 855 | | | China | 471 | | | 195 | | | 152 | | | Spain | 453 | | | 472 | | | 611 | | | Brazil | 406 | | | 359 | | | 350 | | | Italy | 379 | | | 372 | | | 652 | | | All other countries | 3,977 | | | 3,566 | | | 3,863 | | | Total net revenues | $ | 45,804 | | | $ | 33,266 | | | $ | 32,753 | |
Long-lived assets, primarily net property and equipment, by geographic area were as follows: | | | | | | | | | | | | | as of December 31 (in millions) | 2020 | | 2019 | | United States and Puerto Rico | $ | 3,354 | | | $ | 2,026 | | | Europe | 1,534 | | | 646 | | | All other | 360 | | | 290 | | | Total long-lived assets | $ | 5,248 | | | $ | 2,962 | |
|